home / stock / imab / imab quote
Last: | $1.50 |
---|---|
Change Percent: | 0.0% |
Open: | $1.56 |
Close: | $1.50 |
High: | $1.609 |
Low: | $1.5 |
Volume: | 149,073 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.5 | $1.56 | $1.5 | $1.609 | $1.5 | 149,073 | 07-04-2024 |
$1.5 | $1.56 | $1.5 | $1.609 | $1.5 | 148,522 | 07-03-2024 |
$1.58 | $1.61 | $1.58 | $1.63 | $1.57 | 147,129 | 07-02-2024 |
$1.62 | $1.67 | $1.62 | $1.67 | $1.59 | 103,149 | 07-01-2024 |
$1.67 | $1.71 | $1.67 | $1.7334 | $1.6 | 110,690 | 06-28-2024 |
$1.69 | $1.72 | $1.69 | $1.7694 | $1.66 | 99,601 | 06-27-2024 |
$1.705 | $1.7 | $1.705 | $1.76 | $1.68 | 163,140 | 06-26-2024 |
$1.72 | $1.71 | $1.72 | $1.74 | $1.6906 | 54,741 | 06-25-2024 |
$1.72 | $1.67 | $1.72 | $1.73 | $1.67 | 85,140 | 06-24-2024 |
$1.68 | $1.71 | $1.68 | $1.72 | $1.68 | 95,766 | 06-21-2024 |
$1.69 | $1.76 | $1.69 | $1.775 | $1.67 | 187,773 | 06-20-2024 |
$1.77 | $1.8 | $1.77 | $1.81 | $1.76 | 150,203 | 06-19-2024 |
$1.77 | $1.8 | $1.77 | $1.81 | $1.76 | 150,203 | 06-18-2024 |
$1.82 | $1.82 | $1.82 | $1.84 | $1.77 | 145,856 | 06-17-2024 |
$1.84 | $1.85 | $1.84 | $1.86 | $1.83 | 98,437 | 06-14-2024 |
$1.86 | $1.84 | $1.86 | $1.86 | $1.84 | 63,884 | 06-13-2024 |
$1.85 | $1.87 | $1.85 | $1.87 | $1.83 | 222,343 | 06-12-2024 |
$1.86 | $1.84 | $1.86 | $1.89 | $1.84 | 132,787 | 06-11-2024 |
$1.855 | $1.91 | $1.855 | $1.91 | $1.84 | 182,113 | 06-10-2024 |
$1.88 | $1.88 | $1.88 | $1.9 | $1.83 | 256,372 | 06-07-2024 |
News, Short Squeeze, Breakout and More Instantly...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...
Encouraging objective responses were observed in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR), mainly in patients previously treated with checkpoint inhibitors Phase 1 dose-escalation data demonstrated that ragistomig monotherapy can be...